Stockscreener 앱 받기
0.8549
1.72%
-0.015
시장 영업 전:
.86
0.00505
+0.59%
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia
Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa
Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus
Dermata Therapeutics IncAnnounces Topline Results From Phase 3 Trial Of XyngariSEC Filing - marketscreener.com
Dermata reports early success in acne treatment with XYNGARI - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World
Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada
Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Dermata Therapeutics stock hits 52-week low at $1 - Investing.com
Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph
XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results - Investing.com
Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - MarketScreener
XYNGARI shows promise in Phase 3 acne trial - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan
Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com India
Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com
Dermata Therapeutics, Inc. SEC 10-K Report - TradingView
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR
Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail
Head-To-Head Analysis: Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) - The AM Reporter
Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World
Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com
Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire
0.39%
3.66%
자본화:
|
볼륨(24시간):